Aspirin, Other OTC Painkillers May Increase Colon Cancer Risk In Some People: Study

While aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) may help reduce the risk of colorectal cancer in many people, new research suggests that for a small part of the population, with a specific set of genes, the medications may actually increase their colon cancer risk. 

In a study published in the Journal of the American Medical Association (JAMA) on March 17, researchers looked at data on 16,000 people of European descent and found a 30% decreased risk of colon cancer from taking over-the-counter painkillers like Bayer and Motrin. However, between 4% and 9% of the population of those examined have TA or AA genotypes, which appear to cause those same drugs to nearly double their risk of colorectal cancer.

Researchers indicate that the new findings could prove useful to doctors trying to determine whether patient’s should regularly use OTC painkillers for certain ailments and to determine who the drugs would aid in preventing colon cancer.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“In this genome-wide investigation of gene x environmental interactions, use of aspirin and/or NSAIDs was associated with lower risk of colorectal cancer, and this association differed according to genetic variation at 2 SNPs at chromosomes 12 and 15,” the researchers concluded. “Validation of these findings in additional populations may facilitate targeted colorectal cancer prevention strategies.”

About 137,000 people in the U.S. were diagnosed with colorectal cancer in 2014, according to the American Cancer Society. With a little more than 50,000 of those people likely to die from the disease, colon cancer is the third most commonly diagnosed form of cancer in the United States, and the third leading cause of cancer death.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Cartiva is urging federal judges to reject consolidation of toe-implant lawsuits, arguing that an MDL would interfere with individual claim resolutions that the company says are already being handled efficiently outside of court.
The first Covidien Symbotex mesh bellwether has been restored to the 2026 trial calendar, signaling renewed momentum in a litigation where more than 2,000 similar claims are still awaiting resolution.
In the first federal trial over claims of Uber driver sexual assaults, a lawsuit involving the rape of a passenger will go before a jury on January 13.